SCHEMBL2998082

SCHEMBL2998082

CCOC(=O)N1CCc2sc(NC(=O)OC(C)(C)C)c(OC)c2CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.46
MAPT P10636 11/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
TSHR P16473 3/20 0.42
NPSR1 Q6W5P4 6/20 0.41
ALDH1A1 P00352 6/20 0.41
HPGD P15428 3/20 0.41
HTT P42858 2/20 0.41
PKM P14618 1/20 0.41
BLM P54132 1/20 0.41
GPR55 Q9Y2T6 1/20 0.41
ALOX15 P16050 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
TP53 P04637 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ATM Q13315 1/20 0.40
ADORA3 P0DMS8 1/20 0.39
PDE4D Q08499 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2995547 0.76 MAPT (0.44) ADORA1MAPTSMN1; SMN2TSHRNPSR1
SCHEMBL2994362 0.76 MAPT (0.44) ADORA1MAPTSMN1; SMN2TSHRNPSR1
SCHEMBL3008995 0.75 MAPT (0.43) ADORA1MAPTSMN1; SMN2TSHRNPSR1
SCHEMBL3001072 0.75 ADORA1 (0.45) ADORA1MAPTSMN1; SMN2TSHRNPSR1
SCHEMBL3007349 0.75 L3MBTL1 (0.44) ADORA1MAPTSMN1; SMN2TSHRALDH1A1
SCHEMBL2989298 0.74 MAPT (0.42) ADORA1MAPTSMN1; SMN2TSHRNPSR1
SCHEMBL3001775 0.74 MAPT (0.43) ADORA1MAPTSMN1; SMN2TSHRNPSR1
SCHEMBL7795815 0.71 ADORA1 (0.69) ADORA1MAPTSMN1; SMN2TSHRNPSR1
SCHEMBL937489 0.70 ADORA1 (0.85) ADORA1MAPTSMN1; SMN2TSHRALDH1A1
SCHEMBL13354792 0.70 MAPT (0.40) ADORA1MAPTTSHRNPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778243-B1 SUBSTITUTED AZEPINE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS ATHERSYS INC (US) 2012-10-31 EP disclosed
US-20100190772-A1 Substituted Azepine Derivatives As Serotonin Receptor Modulators BENNANI YOUSSEF L 2010-07-29 US disclosed
US-7718647-B2 Substituted azepine derivatives as serotonin receptor modulators ATHERSYS, INC. (US) 2010-05-18 US disclosed
US-20060003990-A1 Substituted azepine derivatives as serotonin receptor modulators ATHERSYS, INC. 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060003990-A1 Substituted azepine derivatives as serotonin receptor modulators HTR5A, HTR4, HTR7 ADORA1 47/4885MAPT 4268/4885SMN1; SMN2 4252/4885
US-20100190772-A1 Substituted Azepine Derivatives As Serotonin Receptor Modulators HTR5A, HTR4, HTR2C ADORA1 50/4885MAPT 4104/4885SMN1; SMN2 4290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.